The possibilities of statins in the prevention of chronic diffuse kidney disease progressing


  • V. V. Syvolap
  • M. P. Gerasko



Dyslipidemia, Glomerular Filtration, Kidney Disease, Therapy


Aim. To summarize the evidence from recent randomized clinical trials on the efficacy of statin therapy of chronic diffuse kidney disease.

Methods and results. The prospects of using statins in the prevention and treatment of chronic diffuse kidney diseases are considered in this review. The results of the international multicentric  randomized trials of the comparative efficiency of various preparations belonging to the given class were shown; their pleuotropic effects, utmost safety and tolerance, the advantages of some particular representatives in the given class preparations in patients with kidney pathology were revealed.

Conclusion. The review supports the use of statins in patients with chronic diffuse kidney disease.


Alsheikh-Ali, A. A., Ambrose, M. S., Kuvin, J. T., & Karas, R. H. (2005) The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation, 111(23), 3051–3057.

(2012) American Stroke Association; American Heart Association. Heart dis. Retrieved from

Ashton, E., Windebank, E., Skiba, M., Reid, C., Schneider, H., Rosenfeldt, F., et al. (2011) Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol, 146(3), 404–407. doi: 10.1016/j.ijcard.2009.12.028.

Athyros, V. G., Mikhailidis, D. P., Papageorgiou, A. A., Symeonidis, A. N., Pehlivanidis, A. N., Bouloukos, V. I., & Elisaf, M. (2004). The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol, 57(7), 728–734. doi: 10.1136/jcp.2003.012989.

Bianchi, S., Bigazzi, R., Caiazza, A., Campese, V. M. (2003) A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis, 41(3), 565–570. doi:10.1053/ajkd.2003.50140.

Bonow, R. O., Bennett, S., Casey, D. E. Jr., Ganiats, T. G., Hlatky, M. A., Konstam, M. A., et al (2005) ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol, 46(6), 1144–1178.

Bybee, K. A., Lee, J. H., & O’Keefe, J. H. (2008) Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Curr Med Res Opin, 24(4), 1217–1229. doi: 10.1185/030079908X292001.

Charach, G., George, J., Afek, A., Wexler, D., Sheps, D., Keren, G., & Rubinstein, A. (2009) Antibodies to oxidized LDL as predictors of morbidity and mortality in patients with chronic heart failure. J Card Fail, 15(9), 770–774. doi: 10.1016/j.cardfail.2009.05.009.

Collins, R., Armitage, J., Parish, S., Sleigh, P., & Peto, R. (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo- controlled trial. Lancet, 361(9374), 2005–2016. doi:

Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., et al. (2009) AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med., 360(14), 1395–1407. doi: 10.1056/NEJMoa0810177.

Folkeringa, R. J., Van Kraaij, D. J., Tieleman, R. G., Nieman, F. H., Pinto, Y. M., & Crijns, H. J. (2006). Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail, 12(2), 134–138. doi:10.1016/j.cardfail.2005.10.014.

Foody, J. M., Shah, R., Galusha, D., Masoudi, F. A., Havranek, E. P., & Krumholz, H. M. (2006) Statins and mortality among elderly patients hospitalized with heart failure. Circulation, 113(8), 1086–1092.

García-Rodríguez, L. A., González-Pérez, A., Stang, M. R., Wallander, M A., & Johansson, S. (2008) The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf, 17(10), 953–961. doi: 10.1002/pds.1602.

Guthrie, R. M., & Martin, D. R. (2007). The safety of rosuvastatin: effects on renal and hepatic function. Expert Opin Drug Saf, 6(5), 573–581. doi: 10.1517/14740338.6.5.573.

Holdaas, H., Holme, I., Schmieder, R. E., Jardine, A. G., Zannad, F., Norby, G. E., et al. (2011) AURORA study group. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol., 22(7), 1335–1341. doi: 10.1681/ASN.2010090987.

Hong, Y. J., Jeong, M. H., Hachinohe, D., Ahmed, K., Choi, Y. H., Cho, S. H., et al. (2011) Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J., 75(2), 398–406. doi: 10.1253/circj.CJ-10-0658.

Horwich, T. B., MacLellan, W. R., & Fonarow, G. C. (2004). Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol., 43(4), 642–648. doi: 10.1016/j.jacc.2003.07.049.

Insull, W. Jr., Ghali, J. K., Hassman, D. R., Gandhi, S. K., & Miller, E. (2007) Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc., 82(5), 543–550. doi:10.4065/82.5.543.

Joyce, M., Kelly, C., Winter, D., Chen, G., Leahy, A., & Bouchier-Hayes, D. (2001) Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res, 101(1), 79–84. doi: 10.1006/jsre.2001.6256.

Keller, D. M. (2010) PLANET I and II: Atorvastatin beats rosuvastatin for protecting kidneys in diabetic and nondiabetic patients. Retrieved from http://www.theheart. org/article/

Khush, K. K., Waters, D. D., Bittner, V., Deedwania, P. C., Kastelein, J. J., Lewis, S. J., & Wenger, N. K. (2007) Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation, 115(5), 576–583. doi: 10.1161/CIRCULATIONAHA.106.625574.

Kimura, S., Inoguchi, T., Yokomizo, H., Maeda, Y., Sonoda, N., & Takayanagi, R. (2012) Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy, 14(7), 666–669. doi: 10.1111/j.1463-1326.2012.01566.x.

Kimura, K., Shimano, H., Yokote, K., Urashima, M., & Teramoto, T. (2010) Effects of pitavastatin on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J.Atheroscler. Thromb., 17, 601–609. doi: 10.5551/jat.3764.

Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., et al. (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med, 357(22), 2248–2261. doi: 10.1056/NEJMoa0706201.

Koren, M. J., Davidson, M. H., Wilson, D. J., Fayyad, R. S., Zuckerman, A., & Reed, D. P. (2009) Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis, 53(5), 741–750. doi: 10.1053/j.ajkd.2008.11.025.

Koren, M. J., & Hunninghake, D. B. (2004) Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol, 44(9), 1772–1779.

Kostapanos, M. S., Milionis, H. J., & Elisaf, M. S. (2010) Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs., 10(1), 11–28. doi: 10.2165/13168600-000000000-00000.

Lavie, C. J., & Mehra, M. R. (2009) Statins and advanced heart failure-alive but barely breathing after CORONA and GISSI-HF. Congest Heart Fail, 15(4), 157–158. doi: 10.1111/j.1751-7133.2009.00089.x.

Lavie, C. J., & Milani, R. V. (2010) High-dose atorvastatin in acute coronary and cerebrovascular syndromes. JACC Cardiovasc Interv, 3(3), 340–342. doi: 10.1016/j.jcin.2010.01.002.

Lavie, C. J., Milani, R. V., & O’Keefe, J. H. (2010) Does the choice of statin really matter? Postgrad Med, 122(3), 243–247. doi: 10.3810/pgm.2010.05.2165.

Lee, C. W., Kang, S. J., Ahn, J. M. Song, H. G., Lee, J. Y., Kim, W. J., et al. (2012) Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial). Am J Cardiol, 109(12), 1700–1704. doi: 10.1016/j.amjcard.2012.01.399.

Leiter, L. A., Rosenson, R. S., Stein, E., Reckless, J. P., Schulte, K. L., Schleman, M., et al. (2007) Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis, 194(2), e154–e164. doi: 10.1016/j.atherosclerosis.2006.12.001.

März, W., Genser, B., Drechsler, C., Krane, V., Grammer, T. B., Ritz, E., et al. (2011) Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol., 6(6), 1316–1325. doi: 10.2215/CJN.09121010.

Massie, B. M., & Shah, N. B. (1997) Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J, 133(6), 703–712. doi: 10.1016/S0002-8703(97)70173-X.

McAfee, A. T., Ming, E. E., Seeger, J. D., Quinn, S. G., Ng, E. W., Danielson, J. D., et al. (2006) The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf., 15(7), 444–453.

H.J. Milionis, E. Rizos, M. Kostapanos et al.Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin. – 2006. – Vol. 22(6). – P. 1123–1131.

Nicholls, S. J., Ballantyne, C. M., Barter, P. J. Chapman, M. J., Erbel, R. M., Libby, P. et al. (2011). Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med., 365(22), 2078–2087. doi: 10.1056/NEJMoa1110874.

O’Donnell, M. P., Kasiske, B. L., Kim, Y., Schmitz, P. G., & Keane, W. F. (1993). Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis., 22(1), 83–89. doi: 10.1016/S0272-6386(12)70172-5.

Ray, J. G., Gong Y., Sykora, K., & Tu, J. V. (2005) Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med., 165(1), 62–67.

Ridker, P. M., Danielson, E., Fonseca, F. A. Genest, J., Gotto, A. M., Kastelein, J. J. P., et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med., 359(21), 2195–2207. doi: 10.1056/NEJMoa0807646.

Sandhu, S., Wiebe, N., Fried, L. F., & Tonelli, M. (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol, 17(7), 2006–2016. doi: 10.1681/ASN.2006010012.

Sever, P. S., Chang, C. L., Gupta, A. K., Whitehouse, A., & Poulter, N. R. (2011) The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J., 32(20), 2525–2532. doi: 10.1093/eurheartj/ehr333.

Shepherd, J., Kastelein, J. J., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., et al. (2007) Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol, 2(6), 1131–1139.

Sola, S., Mir, M. Q., Rajagopalan, S. Helmy, T., Tandon, N., & Khan, B. V. (2005) Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail, 11(8), 607–612. doi:10.1016/j.cardfail.2005.05.011.

Strippoli, G. F. M., Navaneethan, S. D., Johnson, D. W., Perkovic, V., Pellegrini, F., Nicolucci, A., & Craig, J. C. (2008) Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials. BMJ., 336, 645–651. doi: 10.1136/bmj.39472.580984.

Takagi, H., & Umemoto, T. (2012) Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: a meta-analysis of randomized trials. Int J Cardiol., 155(2), 296–299. doi: 10.1016/j.ijcard.2011.11.079.

Tavazzi, L., Maggioni, A. P., Marchioli, R., Barlera, S., Franzosi, M. G., Latini, R., et al (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet., 372(9645), 1231–1239. doi: 10.1016/S0140-6736(08)61240-4.

Tsutamoto, T., Sakai, H., Ibe, K., Yamaji, M., Kawahara, C., Nakae, I., et al. (2011) Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy. Circ J., 75(9), 2160–2166. doi: 10.1253/circj.CJ-11-0222.

Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F., Ruf, G., & Ritz, E. (2005). Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med., 353(3), 238–248.

Xu, M., Yuan, G., & Wei, F. (2010) Effect of atorvastatin in patients with chronic heart failure—insights from randomized clinical trials. Arch Med Sci., 6(6), 866–873. doi: 10.5114/aoms.2010.19293.

How to Cite

Syvolap VV, Gerasko MP. The possibilities of statins in the prevention of chronic diffuse kidney disease progressing. Zaporozhye Medical Journal [Internet]. 2015Jun.15 [cited 2024Jun.18];17(3). Available from: